Fractyl Health (GUTS) Change in Accured Expenses (2023 - 2026)
Fractyl Health's (GUTS) quarterly Change in Accured Expenses came in at -$2.9 million in Q1 2026, down 475.51% YoY from $780000.0 in Q1 2025, and down 1633.14% on a QoQ basis from -$169000.0 in Q4 2025.
Fractyl Health (GUTS) Change in Accured Expenses (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Change in Accured Expenses data on file, last reported at -$2.9 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 475.51% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 192.04% YoY) and the FY2025 annual result came in at $414000.0, down 92.68% from the prior year.
- Change in Accured Expenses fell to -$2.9 million in Q1 2026, from -$169000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q1 2024 to a low of -$2.9 million in Q1 2026.
- A 4-year average of $283230.8 and a median of $367000.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses surged 2430.77% — and 2026, when it sank 475.51%.
- Tracing GUTS's Change in Accured Expenses over 4 years: stood at $367000.0 in 2023, then jumped by 613.35% to $2.6 million in 2024, then plunged by 106.46% to -$169000.0 in 2025, then sank by 1633.14% to -$2.9 million in 2026.
- The last three Change in Accured Expenses figures came in at -$2.9 million (Q1 2026), -$169000.0 (Q4 2025), and -$811000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | 1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Mn |
| Jun 30, 2026 | 1.04 Mn |
| Mar 31, 2026 | -2.93 Mn |
| Mar 31, 2026 | -2.93 Mn |
| Dec 31, 2025 | -169,000.00 |
| Dec 31, 2025 | -169,000.00 |
| Sep 30, 2025 | -811,000.00 |
| Sep 30, 2025 | -811,000.00 |
| Jun 30, 2025 | 614,000.00 |
| Jun 30, 2025 | 614,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Mar 31, 2025 | 780,000.00 |
| Dec 31, 2024 | 2.62 Mn |
| Dec 31, 2024 | 2.62 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Mar 31, 2024 | 2.85 Mn |
| Mar 31, 2024 | 2.85 Mn |